E
40.09
-1.26 (-3.05%)
| Previous Close | 41.35 |
| Open | 41.32 |
| Volume | 2,211,802 |
| Avg. Volume (3M) | 2,880,443 |
| Market Cap | 10,792,329,216 |
| Price / Earnings (TTM) | 19.27 |
| Price / Earnings (Forward) | 14.20 |
| Price / Sales | 5.14 |
| Price / Book | 5.10 |
| 52 Weeks Range | |
| Earnings Date | 28 Oct 2025 |
| Profit Margin | 27.99% |
| Operating Margin (TTM) | 33.64% |
| Diluted EPS (TTM) | 2.19 |
| Quarterly Revenue Growth (YOY) | 30.60% |
| Quarterly Earnings Growth (YOY) | 327.70% |
| Total Debt/Equity (MRQ) | 8.78% |
| Current Ratio (MRQ) | 3.50 |
| Operating Cash Flow (TTM) | 842.59 M |
| Levered Free Cash Flow (TTM) | 559.13 M |
| Return on Assets (TTM) | 18.05% |
| Return on Equity (TTM) | 30.22% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Exelixis, Inc. | Bearish | Bullish |
AIStockmoo Score
-0.3
| Analyst Consensus | -0.5 |
| Insider Activity | 3.0 |
| Price Volatility | 2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -3.5 |
| Average | -0.30 |
|
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 2.20% |
| % Held by Institutions | 93.99% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 51.00 (TD Cowen, 27.21%) | Buy |
| Median | 45.00 (12.25%) | |
| Low | 30.00 (Wells Fargo, -25.17%) | Hold |
| Average | 44.00 (9.75%) | |
| Total | 5 Buy, 4 Hold | |
| Avg. Price @ Call | 39.01 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| UBS | 06 Nov 2025 | 40.00 (-0.22%) | Hold | 40.80 |
| Barclays | 05 Nov 2025 | 41.00 (2.27%) | Hold | 40.37 |
| 17 Sep 2025 | 40.00 (-0.22%) | Hold | 40.44 | |
| HC Wainwright & Co. | 05 Nov 2025 | 49.00 (22.22%) | Buy | 40.37 |
| Morgan Stanley | 05 Nov 2025 | 45.00 (12.25%) | Buy | 40.37 |
| 21 Oct 2025 | 44.00 (9.75%) | Buy | 36.13 | |
| TD Cowen | 05 Nov 2025 | 51.00 (27.21%) | Buy | 40.37 |
| Leerink Partners | 21 Oct 2025 | 48.00 (19.73%) | Buy | 36.13 |
| RBC Capital | 21 Oct 2025 | 45.00 (12.25%) | Hold | 36.13 |
| Wells Fargo | 21 Oct 2025 | 30.00 (-25.17%) | Hold | 36.13 |
| Goldman Sachs | 17 Sep 2025 | 47.00 (17.24%) | Buy | 40.44 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HEFTI BRENDA | 44.01 | - | 30,170 | 1,327,782 |
| Aggregate Net Quantity | 30,170 | |||
| Aggregate Net Value ($) | 1,327,782 | |||
| Aggregate Avg. Buy ($) | 44.01 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| HEFTI BRENDA | Officer | 03 Dec 2025 | Acquired (+) | 30,170 | 44.01 | 1,327,782 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |